Civic Intelligence

Abzyme Research Foundation

990EZ • Fiscal year 2023 • EIN 27-3438658

Jan 01, 2023 to Dec 31, 2023 • Filed on Jul 09, 2025

Organization ProfileWWW.ENDHIV.COM
67 Irving Place 12th FloorNew York, NY 10003

(347) 967-3734

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on this filing.

Source year 2023

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on this filing.

Source year 2023

Net Margin

1st percentile

-31304%

Higher net margin than 1% of similar nonprofits.

2023 filings • NTEE H • <$500k nonprofits • Source year 2023

Top Officer Pay

89th percentile

$0

Higher top officer pay than 89% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2023 filings • NTEE H • <$500k nonprofits • Source year 2023

Asset Growth

49th percentile

-2.1%

Faster asset growth than 49% of similar nonprofits.

2023 filings • NTEE H • <$500k nonprofits • Annualized from 2022 to 2023

Revenue Growth

14th percentile

-56%

Faster revenue growth than 14% of similar nonprofits.

2023 filings • NTEE H • <$500k nonprofits • Annualized from 2022 to 2023

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Down

$328,979

Down $7,199 (-2.1%) from 2022

Net Assets

Down

$328,979

Down $7,199 (-2.1%) from 2022

Liabilities

-

No earlier filing loaded for comparison.

Revenue And Expenses
Liabilities / RevenueScore unavailableNet Margin1st percentile

Revenue

Down

$23

Down $29 (-56%) from 2022

Expenses

Up

$7,223

Up $1,484 (+26%) from 2022

Net Income

Down

-$7,200

Down $1,513 (-27%) from 2022

Historical Trend

Balance Sheet Trend

Asset Growth49th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$400K$300K$200K$100K$0Assets 2017: $385,535Liabilities 2017: $2,215Net Assets 2017: $383,3202017Assets 2018: $351,372Liabilities 2018: $10,750Net Assets 2018: $340,6222018Assets 2019: $353,342Liabilities 2019: $0Net Assets 2019: $353,3422019Assets 2020: $344,776Liabilities 2020: $0Net Assets 2020: $344,7762020Assets 2021: $341,865Liabilities 2021: $0Net Assets 2021: $341,8652021Assets 2022: $336,178Net Assets 2022: $336,1782022Assets 2023: $328,979Net Assets 2023: $328,9792023Assets 2024: $335,298Net Assets 2024: $335,2982024

Highlighted filing

2023

Assets$328,979
Liabilities-
Net Assets$328,979
Open 2023 Filing

Operations Trend

Revenue Growth14th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$1.0M$500K$0-$500K-$1.0MRevenue 2017: $172,225Expenses 2017: $744,547Net Income 2017: -$572,3222017Revenue 2018: $84,666Expenses 2018: $127,364Net Income 2018: -$42,6982018Revenue 2019: $60,108Expenses 2019: $32,293Net Income 2019: $27,8152019Revenue 2020: $5,394Expenses 2020: $13,960Net Income 2020: -$8,5662020Revenue 2021: $139Expenses 2021: $3,050Net Income 2021: -$2,9112021Revenue 2022: $52Expenses 2022: $5,739Net Income 2022: -$5,6872022Revenue 2023: $23Expenses 2023: $7,223Net Income 2023: -$7,2002023Revenue 2024: $10,001Expenses 2024: $3,682Net Income 2024: $6,3192024

Highlighted filing

2023

Revenue$23
Expenses$7,223
Net Income-$7,200
Open 2023 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2023 to Dec 31, 2023
Signed
Jul 9, 2025
Return Version
2023v6.0
Gross Receipts
$23
Mission and Program Overview

Mission

Advance the development of abzyme technology in the hopes of producing the world's first effective hiv vaccine and improved treatment for over 36 million hiv-positive people worldwide.

The successful completion of the pre-investigational new drug meeting with the fda as wellas the initiation of a scale-up of the manufacturing of the vaccine compound.

Program Services

DescriptionGrantsExpenses
ADVANCE THE DEVELOPMENT OF ABZYME TECHNOLOGY IN THE HOPES OF PRODUCING THE WORLD'S FIRST EFFECTIVE HIV VACCINE AND IMPROVED TREATMENT FOR OVER 36 MILLION HIV POSITIVE PEOPLE WORLDWIDE--
Compensation and Service Providers
Top Officer Pay89th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
ZACHARY BARNETTDirector-$0--
VALERIE KERRDirector-$0--
BETH MILLER SAKSDirector-$0--
TIM VOLKDirector-$0--
ADAM MACLEANChairman-$0--
MICHAEL JEFVERTChairman-$0--
NICHOLAS SMITHTreasurer-$0--
AIMEE A DROUINSecretary-$0--
Filing and Contact Details

Filer

Filer Name
Abzyme Research Foundation
EIN
27-3438658
Phone
3479673734
Address
67 IRVING PLACE 12TH FLOOR, NEW YORK, NY 10003

Signing Officer

Name
Zachary Barnett
Title
Director
Signed
2025-07-09
Discuss with paid preparer
Yes

Preparer

Firm
George Dimov CPA
Address
211 E 43rd Street Suite 628, NEW YORK, NY 10017
Preparer
George Dimov CPA
Phone
8338291120
Supplemental Narrative

Additional Explanations

Other Assets.1

“Investment in Covalent Bioscience - Beginning $265658 Investment in Covalent Bioscience - Ending $265658”

Other Assets.2

“American Express Credit Card - Beginning $1574 American Express Credit Card - Ending $2825”

Raw XML Appendix141 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0THE ORGANIZATION
IRS990EZ/BooksInCareOfDetail/PhoneNum03479673734
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt067 IRVING PLACE 12TH FL
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0NEW YORK
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0NY
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd010003
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt068947
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt060496
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-7200
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt06897
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0336179
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0328979
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrossReceiptsAmt023
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InvestmentIncomeAmt02
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0336179
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0328979
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0336179
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0328979
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt01.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt11.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt41.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt51.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt61.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt71.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0ZACHARY BARNETT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1VALERIE KERR
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2BETH MILLER SAKS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3TIM VOLK
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4ADAM MACLEAN
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5MICHAEL JEFVERT
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6NICHOLAS SMITH
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm7AIMEE A DROUIN
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4Chairman
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Chairman
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6Treasurer
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt7Secretary
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherAssetsTotalDetail/BOYAmt0267232
IRS990EZ/OtherAssetsTotalDetail/EOYAmt0268483
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0THE SUCCESSFUL COMPLETION OF THE PRE-INVESTIGATIONAL NEW DRUG MEETING WITH THE FDA AS WELLAS THE INITIATION OF A SCALE-UP OF THE MANUFACTURING OF THE VACCINE COMPOUND.
IRS990EZ/ProgramServiceRevenueAmt021
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0ADVANCE THE DEVELOPMENT OF ABZYME TECHNOLOGY IN THE HOPES OF PRODUCING THE WORLD'S FIRST EFFECTIVE HIV VACCINE AND IMPROVED TREATMENT FOR OVER 36 MILLION HIV POSITIVE PEOPLE WORLDWIDE
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/SalariesOtherCompEmplBnftAmt0326
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0NY
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt07223
IRS990EZ/TotalRevenueAmt023
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.ENDHIV.COM
IRS990ScheduleA/First5Years170Ind0X
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt00
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.00000
IRS990ScheduleA/PublicSupportTotal170Amt00
IRS990ScheduleA/SubstantialContributorsTotAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/TotalSupportAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Investment in Covalent Bioscience - Beginning $265658 Investment in Covalent Bioscience - Ending $265658
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1American Express Credit Card - Beginning $1574 American Express Credit Card - Ending $2825
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Assets.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Assets.2
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0ZACHARY BARNETT
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Director
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-07-09
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0ABZYME RESEARCH FOUNDATION
ReturnHeader/Filer/BusinessNameControlTxt0ABZY
ReturnHeader/Filer/EIN0273438658
ReturnHeader/Filer/PhoneNum03479673734
ReturnHeader/Filer/USAddress/AddressLine1Txt067 IRVING PLACE 12TH FLOOR
ReturnHeader/Filer/USAddress/CityNm0NEW YORK
ReturnHeader/Filer/USAddress/StateAbbreviationCd0NY
ReturnHeader/Filer/USAddress/ZIPCd010003
ReturnHeader/IRSResponsiblePrtyInfoCurrInd0true
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0823109419
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0George Dimov CPA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0211 E 43rd Street Suite 628
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0NEW YORK
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0NY
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd010017
ReturnHeader/PreparerPersonGrp/PhoneNum08338291120
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0GEORGE DIMOV CPA
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02025-07-09T11:22:40-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02023-01-01
ReturnHeader/TaxPeriodEndDt02023-12-31
ReturnHeader/TaxYr02023

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2023 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$328,979
Liabilities
-
Net assets
$328,979
Revenue
$23
Expenses
$7,223
Net income
-$7,200
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$3.35$3.35$0.10$0.04$0.06
2023Detailed filing. Detailed filing data is available for this year.$3.29$3.29$0.00$0.07$0.07
2022Detailed filing. Detailed filing data is available for this year.$3.36$3.36$0.00$0.06$0.06
2021Detailed filing. Detailed filing data is available for this year.$3.42$0.00$3.42$0.00$0.03$0.03
2020Detailed filing. Detailed filing data is available for this year.$3.45$0.00$3.45$0.05$0.14$0.09
2019Detailed filing. Detailed filing data is available for this year.$3.53$0.00$3.53$0.60$0.32$0.28
2018Detailed filing. Detailed filing data is available for this year.$3.51$0.11$3.41$0.85$1.27$0.43
2017Detailed filing. Detailed filing data is available for this year.$3.86$0.02$3.83$1.72$7.45$5.72